Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Teva
Cantor Fitzgerald
Cerilliant
Covington
Johnson and Johnson
Moodys
Argus Health
Boehringer Ingelheim

Generated: July 16, 2018

DrugPatentWatch Database Preview

ENTECAVIR Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Entecavir patents expire, and when can generic versions of Entecavir launch?

Entecavir is a drug marketed by Accord Hlthcare, Amneal Pharms, Aurobindo Pharma Ltd, Breckenridge Pharm, Casi Pharms Inc, Cipla Ltd, Hetero Labs Ltd V, Par Pharm Inc, Prinston Inc, Teva Pharms Usa, and Zydus Pharms Usa Inc. and is included in eleven NDAs.

The generic ingredient in ENTECAVIR is entecavir. There are seventeen drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the entecavir profile page.
Drug patent expirations by year for ENTECAVIR
Synonyms for ENTECAVIR
1333204-94-6
142217-69-4
2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one
2-amino-9-((1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)-1,9-dihydro-6H-purin-6-one
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylene-cyclopentyl]-1H-purin-6-one
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylene-cyclopentyl]-3H-purin-6-one
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one hydrate (1:1)
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-3H-purin-6-one
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-6,9-dihydro-1H-purin-6-one
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-6,9-dihydro-3H-purin-6-one
2-Amino-9-[(1S,3R,4S)-4-hydroxy-3-hydroxymethyl-2-methylene-cyclopentyl]-3,9-dihydro-purin-6-one
209216-23-9
217E694
6-H-Purin-6-one-,2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]
6H-Purin-6-one, 2-amino-1,9-dihydro-9-((1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)-
6H-Purin-6-one, 2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-
9-[(1S,3R,4S)-4-Hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]guanine
AB0071164
AB1004838
ABP001043
AC-1593
AC1L4BEC
AJ-45654
AK-77289
AKOS015854916
AKOS015920226
AKOS025312554
AM20080880
AN-1116
anhydrous entecavir
Baraclude
BC677668
BMS 200475
BMS-200475
BMS-200475-01
BR-77289
BRD-K08206212-001-01-2
CAS-142217-69-4
CHEBI:473990
CHEMBL713
CS-3160
D07896
DB00442
DSSTox_CID_26446
DSSTox_GSID_46446
DSSTox_RID_81621
DTXSID4046446
E0899
entecavir (anhydrous)
Entecavir (INN)
Entecavir anhydrous
Entecavir, >=98% (HPLC)
Entecavirum
FT-0083013
GS-6386
HSDB 7334
HY-13623
J90027
KB-95857
KS-00000G4U
LS41110
MFCD00907887
MolPort-005-942-963
MolPort-006-167-546
NCGC00164563-01
NNU2O4609D
NU001508
NU006716
QDGZDCVAUDNJFG-FXQIFTODSA-N
RL01752
S-7388
SC-20106
SCHEMBL15198001
SCHEMBL28648
SQ 34,676
SQ 34676
SQ-34676
Tox21_112192
UNII-NNU2O4609D
ZINC3802690

US Patents and Regulatory Information for ENTECAVIR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Accord Hlthcare ENTECAVIR entecavir TABLET;ORAL 205824-001 Aug 25, 2017 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Prinston Inc ENTECAVIR entecavir TABLET;ORAL 208782-002 Oct 10, 2017 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Breckenridge Pharm ENTECAVIR entecavir TABLET;ORAL 208721-001 Mar 15, 2018 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Amneal Pharms ENTECAVIR entecavir TABLET;ORAL 206652-002 Nov 12, 2015 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Fish and Richardson
Covington
Argus Health
US Department of Justice
Baxter
Harvard Business School
Fuji
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.